Get started
Author

Emily Gruber

IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors
2020 · Lauren Giuffrida, Kevin Sek, et al. · Molecular Therapy · 108
PDF
Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD–Driven Acute Myeloid Leukemia
2021 · Stefan Bjelosevic, Emily Gruber, et al. · Cancer Discovery · 75
PDF
Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia
2025 · Alexander C. Lewis, Emily Gruber, et al. · Cell · 33
Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia
2022 · Joan So, Alexander C Lewis, et al. · EMBO Molecular Medicine · 32
PDF
RNF41 regulates the damage recognition receptor Clec9A and antigen cross-presentation in mouse dendritic cells
2020 · Kirsteen M Tullett, Peck Szee Tan, et al. · eLife · 30
Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia
2020 · Emily Gruber, Rheana L. Franich, et al. · Leukemia · 30
Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma
2022 · Jonathan Wong, Emily Gruber, et al. · Leukemia · 29
PDF
Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells
2022 · Emily Gruber, Joan So, et al. · Cell Reports · 25
Barriers and facilitators to screen for and address social needs in primary care practices in Maryland: a qualitative study
2024 · Sadaf Kazi, Claire Starling, et al. · Frontiers in Health Services · 15
High-Throughput Discovery of Aptamers for Sandwich Assays
2016 · Andrew T. Csordas, Anna Jørgensen, et al. · Analytical Chemistry · 14
Rationally designed chimeric PI3K-BET bromodomain inhibitors elicit curative responses in MYC-driven lymphoma
2023 · Danielle H. Oh, Xiao Ma, et al. · Proceedings of the National Academy of Sciences · 10
The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches
2023 · Emily Gruber, Lev M. Kats · Biochemical Society Transactions · 9
PDF
Epigenetic reprogramming in multiple myeloma—Challenges and opportunities
2025 · Subhasree Kumar, Lev M. Kats, et al. · International Journal of Cancer · 7
Functional and Phenotypic Characterisations of Common Syngeneic Tumour Cell Lines as Estrogen Receptor-Positive Breast Cancer Models
2023 · Maria Lambouras, Charlotte Roelofs, et al. · International Journal of Molecular Sciences · 7
PDF
Understanding social needs screening and demographic data collection in primary care practices serving Maryland Medicare patients
2024 · Claire M. Starling, Marjanna Smith, et al. · BMC Health Services Research · 6
PDF
Association of Participation in the Maryland Primary Care Program With COVID-19 Outcomes Among Medicare Beneficiaries
2023 · Emily Gruber, Chad Perman, et al. · JAMA Network Open · 4
PDF
Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
2025 · Olivia Susanto, Emily Gruber, et al. · Molecular Cancer Therapeutics · 1
Maryland's Integration of Public Health and Primary Care During the COVID- 19 Pandemic: Case Study and Lessons Learned
2023 · Rachel Grisham, Emily Gruber, et al. · Health Security · 1
Menin regulates oncogenic cell identity transcriptional networks in multiple myeloma
2026 · Emily Gruber, Subhasree Kumar, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Abstract 4501: Targeting the epigenetic adaptor protein menin in multiple myeloma.
2026 · Emily Gruber, Sree Kumar, et al. · Cancer Research
Supplementary Table S1 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
2026 · Olivia Susanto, Emily Gruber, et al.
Supplementary Table S4 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
2026 · Olivia Susanto, Emily Gruber, et al.
Supplementary Table S2 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
2026 · Olivia Susanto, Emily Gruber, et al.
Supplementary Figure S5 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
2026 · Olivia Susanto, Emily Gruber, et al.
Supplementary Movie S3 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
2026 · Olivia Susanto, Emily Gruber, et al.
Works count: 53
Citation count: 436
H-index: 10
I10-index: 11
Year
Topic
Type